Evaxion ceo comments on strategic focus

Copenhagen, denmark, nov. 10, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, today announced that it intends to further increase its focus on its lead oncology assets evx-01 and evx-02/03 to bring them to clinical proof of concept followed by out-licensing. the company further plans preclinical partnering of its early-stage programs under its infectious disease platforms.
EVAX Ratings Summary
EVAX Quant Ranking